You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光藥(01558.HK)重組人胰島素注射液獲國家藥監局審批完畢並獲准上市
格隆匯 06-15 19:43

格隆匯6月15日丨東陽光藥(01558.HK)公告,公司自主研究及開發產品重組人胰島素注射液已獲中國國家藥品監督管理局審批完畢並獲准上市。

重組人胰島素是一種利用重組DNA技術生產的人胰島素,適用於治療需要採用胰島素來維持正常血糖水平的糖尿病患者。根據艾美仕中國數據顯示,2019年國內公立醫療機構糖尿病領域藥物銷售金額約為39.2億美元,較2018年增長9%,其中胰島素及其類似物類藥物銷售金額佔糖尿病領域藥物銷售金額的份額為42.5%,是糖尿病治療領域最主要的用藥品種。

該產品為集團首個獲批上市的生物製品藥物,累計投入研發費用約人民幣11,611.47萬元。此外,集團在糖尿病治療領域擁有全面規劃,佈局了完整的產品線。該產品成功獲批上市,有益於拓展集團內分泌及代謝治療領域業務,並進一步豐富了集團的產品組合。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account